Oral pristinamycin for the treatment of resistant Gram-positive infections in patients with cancer: Evaluation of clinical outcomes

Highlights • Pristinamycin is a viable option for treatment of resistant Gram-positive infections in the cancer population. • In a cohort of patients with cancer, 81% achieved cure or suppression of infection using oral pristinamycin as a treatment regimen. • In our experience, pristinamycin does no...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of antimicrobial agents 2016-05, Vol.47 (5), p.391-396
Hauptverfasser:	Teng, J.C, Lingaratnam, S.M, Trubiano, J.A, Thursky, K.A, Slavin, M.A, Worth, L.J
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Anti-Bacterial Agents - administration & dosage Antibiotic resistance Australia Cancer Drug Resistance, Bacterial Enterococcus - classification Enterococcus - drug effects Enterococcus - isolation & purification Female Gram-Positive Bacterial Infections - drug therapy Gram-Positive Bacterial Infections - microbiology Gram-Positive Bacterial Infections - pathology Humans Infectious Disease Male Middle Aged Neoplasms - complications Pristinamycin Pristinamycin - administration & dosage Staphylococcus - classification Staphylococcus - drug effects Staphylococcus - isolation & purification Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Pristinamycin is a viable option for treatment of resistant Gram-positive infections in the cancer population. • In a cohort of patients with cancer, 81% achieved cure or suppression of infection using oral pristinamycin as a treatment regimen. • In our experience, pristinamycin does not have significant drug interactions with chemotherapeutic agents and is well tolerated by patients with cancer.
ISSN:	0924-8579 1872-7913
DOI:	10.1016/j.ijantimicag.2016.01.017